Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes

Ariceta, G., Fakhouri, F., Sartz, L., Miller, B., Nikolaou, V., Cohen, D., Siedlecki, A. M., & Ardissino, G. (2021). Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clinical Kidney Journal, 14(9), 2075–2084. https://doi.org/10.1093/ckj/sfab005
Authors:
Gema Ariceta
Fadi Fakhouri
Lisa Sartz
Benjamin Miller
Vasilis Nikolaou
David Cohen
Andrew M. Siedlecki
Gianluigi Ardissino
Affiliated Authors:
David Cohen
Columbia Affiliation:
Author Keywords:
anaemia
gfr
haemoglobin
thrombosis
thrombotic microangiopathy
elink
Publication Type:
Article
Unique ID:
10.1093/ckj/sfab005
DOI:
10.1093/ckj/sfab005
Journal:
Clinical Kidney Journal
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: